MetaVia 10-Q: $8.8M Cash Into 1Q 2027, $13.8M Nine-Month Loss, Going Concern Stands
MTVA sits 45% above its 52-week low of $0.966.
Summary
MetaVia's Q3 10-Q confirms a $4.6M quarterly net loss and $8.8M of cash it says lasts into 1Q 2027, with a $13.8M nine-month loss, a $162.6M accumulated deficit and a repeated going-concern warning. The 2027 Phase 2 trials depend on raising more capital.
Key Events · Earnings and Guidance · MTVA
-
Q3 Loss and Cash Balance
Net loss of $4.6M, or $0.69 per share, for the quarter ended September 30, 2026, on 6,679,250 weighted average shares. Cash and cash equivalents were $8.8M, down from $10.3M at December 31, 2025.
-
Nine-Month Burn Outpaces Prior Year
Nine-month net loss was $13.8M versus $11.0M a year earlier, with net cash used in operations of $11.7M. R&D rose to $8.2M from $6.6M, driven by DA-1726 direct costs of $6.1M versus $4.1M.
-
Going Concern Repeated
The filing states substantial doubt about the ability to continue as a going concern within one year, citing the $162.6M accumulated deficit and ongoing clinical spending. Management plans to fund through equity, debt, warrant exercises or partnerships.
-
Runway Ends Before 2027 Trials
Cash is expected to last into 1Q 2027, while the 48-week Phase 2 in MetALD/ALD is targeted for 2H 2027 and the vanoglipel combination Phase 2a for 1H 2027; the filing states those programs are contingent on additional financing.
Analysis · MTVA · Life Sciences
The headline numbers were already out this morning, but the full 10-Q is what shows how thin the balance sheet is. Cash fell to $8.8M from $10.3M at December 31, 2025, while nine-month operating burn ran $11.7M — so the runway into 1Q 2027 depends on continued ATM sales and warrant exercises, not on operations. Management repeats the substantial-doubt going-concern language, and the 2027 Phase 2 programs in MetALD/ALD and the vanoglipel combination are contingent on raising more money. Existing holders also face a large overhang: 8.9M warrants outstanding against 6.7M shares, with 8.2M of those struck at $3.10 versus a $1.40 stock price, so they are unlikely to be exercised for cash soon.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTVA was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $0.97 to $13.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.